Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDOLTIB Study
NCT04034862Phase 3Completed
- Sponsor
- University of Liège
- Start
- Oct 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir, lamivudine in human immunodeficiency virus infection (HIV), sponsored by University of Liège. Started Oct 2019; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04034862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034862.